Background: Portal-vein stent combined with one iodine-125 ( 125 I) seed strand has become a new treatment for portal vein tumor thrombosis. However, dosimetric aspects of this irradiation stent have not been reported. Therefore, we aimed to undertake dosimetric analyses comparing portal-vein stents combined with different numbers of 125 I seed strands. Methods: A water cylinder was created by a treatment-planning system to simulate a portal-vein stent. The stent was combined with one, two, or three 125 I seed strands (Groups I, II, and III, respectively). At different prescribed doses (PDs),
IntroductIon
In 2012, 782,500 patients worldwide were newly diagnosed with liver cancer, and 745,500 of these patients died. Shockingly, Chinese patients accounted for 50% of the total number of deaths. [1] Hepatocellular carcinoma (HCC) is the most common histologic subtype of primary liver cancer. The prognosis of advanced HCC remains poor, particularly if patients have portal vein tumor thrombosis (PVTT). [2] Management options are limited and the optimal treatment for HCC patients with PVTT is controversial. In the last decade, combinations of some treatment modalities have been explored to treat HCC with PVTT, of which transarterial chemoembolization (TACE) in combination with stenting of the portal vein is very promising. [3] Percutaneous transhepatic stenting of the portal vein has been used as palliative relief from obstruction but has no therapeutic effect on thrombosis due to a tumor. The concept of endovascular brachytherapy with iridium-192 was reported first in 2007 for tumors of the vena cava. [4] Stenting of the Portal Vein Combined with Different Numbers of Iodine-125 Seed Strands: Dosimetric Analyses I) seed strand has become a new treatment for portal vein tumor thrombosis. However, dosimetric aspects of this irradiation stent have not been reported. Therefore, we aimed to undertake dosimetric analyses comparing portal-vein stents combined with different numbers of 125 I seed strands. Methods: A water cylinder was created by a treatment-planning system to simulate a portal-vein stent. The stent was combined with one, two, or three 125 I seed strands (Groups I, II, and III, respectively). At different prescribed doses (PDs),
125
I seeds of identical activities were loaded on Groups I-III. Conformation number (CN), external volume index, and homogeneity index were calculated. Linear regression analyses were used to evaluate the obtained data.
Results: For identical

125
I seed activity, when the 125 I seed strand increased from one chain to two, D 90 (dose delivered to 90% of the target volume) increased by ≥184%; when it increased from two chains to three, D 90 increased by ≥63%. When the PD was 105 Gy and 125 I seed strands increased from one chain to two, V 100 (percentage of the target volume receiving ≥90% of the PD) increased by 158-249%; when it increased from two chains to three, V 100 increased by 7-175%. CN was correlated positively with 125 I seed activity (B = 0.479, P < 0.001) and number of 125 I seed strands (B = 0.201, P < 0.001) and was independent of PD (B = −0.002, P = 0.078). Recently, malignancy-induced stenosis has been managed by implantation of a low dose-rate iodine-125 ( 125 I) seed-loaded stent. [5] [6] [7] [8] Several animal [9, 10] and clinical [11] [12] [13] [14] studies have also demonstrated the short-term efficacy and safety of endovascular placement of a single 125 I seed strand and a stent combined with TACE for HCC with PVTT. However, those studies focused only the seeds activity, number, and effectiveness of 125 I seeds and complications of the modality; dosimetric aspects of a stent combined with 125 I seed strand(s) have seldom been reported.
Conclusions
Clinical reports of treatment of vascular thrombosis have involved stent implantation combined usually with a single 125 I seed strand. However, ensuring a conformal and uniform dose distribution within the tumor target has proved difficult. By simulation of radioactive portal-vein stents combined with different numbers of 125 I seed strands using a treatment-planning system (TPS), we wished to: (i) analyze the characteristics of dosimetric distribution in the tumor target volume; (ii) ascertain the optimal regimen based on calculated dosimetric parameters; and (iii) provide a reference for clinical application.
methods
Simulation of a model of radioactive stents
Using a module within a TPS (Prowess, Concord, CA, USA) based on the American Association of Physicists in Medicine TG43 and TG43U1 reports, we created a water cylinder (1 cm × 1 cm × 10 cm) to simulate a stent in the portal vein. The diameter of the stent was 1 cm, and the length was 10 cm. Along the long axis of the cylinder, the cross-sectional image height was set to 0.5 cm, so 20 layer cross-sectional images (simulated as computed tomography scans) were formed.
Delineation of target volume
An image at the intermediate level was used as a benchmark. The edge of the water cylinder was outlined to simulate the inner boundary of the tumor target volume and then expanded by 0.5 cm to simulate the outside border of the tumor target area. The upper and lower reference images were also outlined and formed seven continuous images. Then, 15 images were delineated. Therefore, the gross tumor volume had a length of 7.5 cm. Delineation of the target volume is shown in Figure 1a .
Treatment planning
Experimentally simulated radioactive stents were combined with one, two, or three Reports have shown that a prescribed dose (PD) of 100-160 Gy is safe and efficacious for 125 I seed interstitial implantation for solid tumors. [15] [16] [17] [18] [19] [20] In addition, the PD recommended for prostate cancer is 145 Gy. [16, 17] Therefore, the PD (in Gy) was set at 105, 125, and 145. At different PDs, 125 I seeds of 0.3, 0.4, 0.5, 0.6, 0.7, and 0.8 mCi (mCi is a unit of radioactivity, which is the number of decay of the nucleus per unit time. 1 mCi = 37 MBq) were loaded on Groups I, II, and III, respectively. To evaluate the dose distribution of the target volume, we recorded the dosimetric parameters of dose-volume histogram (DVH) shown in different PDs and different activities of 
Dosimetric evaluation
The dosimetric quality of our brachytherapy plans was evaluated according to the conformation number (CN), external volume index (EI), and homogeneity index (HI). All parameters were computed on the basis of the DVH.
The CN was defined as:
Where V T, ref is the volume of the target receiving a dose equal to or greater than the PD, V T is the target volume, and V ref is the volume receiving a dose equal to or greater than the PD. The value of the CN is between 0 and 1, where "1" denotes "optimal conformation" and "0" denotes "no conformation. The EI was used to determine irradiation of tissues outside the target volume and was defined as: [22] 
If V ref = V T, ref , an ideal value of "0" is obtained, suggesting that the dose normal tissue receives is less than the PD. The larger the EI, the greater is the volume outside the target volume receiving PD.
The HI was used to describe dose homogeneity within the target volume and was defined as: [22] 
Where V T,1.5ref is the volume of the target receiving a dose ≥150% of the PD. The "ideal" HI is 100%. A larger HI suggests more uniform dose distribution within the target.
Statistical analyses
Statistical analyses were conducted using SPSS version 19.0 (IBM, Armonk, NY, USA). Using linear regression analyses, P < 0.05 (two-tailed) was considered statistically significant.
results
The two-and three-dimensional dose distributions for different activities of 125 I seeds in Groups I, II, and III are shown in Figures 2 and 3 . 
Volume-dose parameters
Dose-volume parameters
The dose-volume parameters V 90 , V 100 , and V 150 at a PD (in Gy) of 105, 125, and 145 for Groups I, II, and III are shown in Figure 4 . Using the definition of dose-volume parameters stated above, for an identical activity of 125 I seed, V 90 , V 100 , and V 150 will decrease with increasing PD. Curves for V 90 , V 100 , and V 150 curves in Figure 4 were consistent with this concept.
For an identical activity of 125 I seed, when the PD was 105 Gy and the 125 I seed strand increased from one chain to two chains, V 100 increased by 158-249%; when 125 I seed strand increased from two chains to three chains, V 100 increased by 7-175%. For an identical activity of 125 I seed, when the PD was 125 Gy and the 125 I seed strand increased from one chain to two chains, V 100 increased by 138-251%; when 125 I seed strand increased from two chains to three chains, V 100 increased by 21-174%. For an identical activity of 125 I seed, when the PD was 145 Gy and the 125 I seed strand increased from one chain to two chains, V 100 increased by 138-248%; when 125 I seed strand increased from two chains to three chains, V 100 increased by 43-169%.
Parameters for assessment of the brachytherapy plan
The parameters for planning assessment (the CN, EI, HI) at a PD (in Gy) of 105, 125, and 145 for Groups I, II, and III are summarized in Table 2 . Using the CN, EI, and HI as dependent variables and the PD, activity of 125 I seeds, and number of 125 I seed strands as independent 
dIscussIon
With increasingly detailed studies of intraluminal implantation of 125 I seed-loaded stents, [23] stenting of the portal vein combined with implantation of 125 I seed strands has become a new treatment of HCC with PVTT. In clinical application of this technology, most researchers have used the formula: obstruction length (mm)/4.5 + 4 to calculate the required number of 125 I seeds. However, the dose distribution in the tumor target has been reported rarely. [13, 14, 24] Luo et al. [14] adopted the formula shown above to calculate the required number of 125 I seeds and, according to the software used to calculate distribution of the 125 I radiation field, the mean radiation dose of PVTT was 142.1 ± 39.9 Gy. Sun et al. [24] chose 0.6 mCi/seed for the implantation of using the formula: obstruction length (cm)/0.5 + 2. Finally, the mean dose absorbed 1 cm from the source axis within 60 days was 40-50 Gy. The activity of 125 I seeds in the study by Chuan-Xing et al. [12] was 0.6-0.8 mCi, and the matched peripheral dose calculated by the TPS was 110-150 Gy.
Review of the literature shows that the calculation methods for dose distribution of 125 I seed strands are different; range of target radiation dose is very broad; radiation dose of normal tissues around the target volume is rarely described; assessment of the brachytherapy plan is absent. Therefore, comparison of clinical efficacy among different studies also becomes difficult. This is also the reason why we choose the criteria for prostate cancer to conduct our study. Dose distribution is the most direct and important factor influencing the outcome of brachytherapy. [25] A change in radiation dose affects local control of the tumor significantly. [26] The American Brachytherapy Society recommends three steps for the assessment of the quality of implantation of 125 I seeds: [27] (i) review distribution of the isodose to offer the most direct assessment of dose coverage; (ii) generate a DVH to obtain volumetric parameters; (iii) determine the CN and HI to evaluate the dosimetric quality of the brachytherapy plan (which may be of value in assessment of the future clinical outcomes). Figures 2 and 3 show that, when stenting of the portal vein was combined with implantation of a single 125 I seed strand and activity of the 125 I seed was 0.3-0.8 mCi, reference isodose curves/surfaces could not completely "wrap" the target volume around the stent. Hence, the target volume (which is not covered by the reference dose) forms a low-dose area, which is likely to cause local recurrence or metastasis of the tumor, leading to stent restenosis and occlusion.
The British Columbia Cancer Agency recommends D 90 >90% PD and V 100 >85% for brachytherapy of prostate cancer. [28] In the present study, when the PD (in Gy) was 105, 125, and 145 and the corresponding seed activity (in mCi) was ≥0.5, ≥0.5, and ≥0.6, respectively, D 90 and V 100 of Group III could meet the requirements mentioned above. When the PD was 105 Gy and seed activity was 0.7 mCi, D 90 and V 100 of Group II were 98.2 Gy and 85.4%; when seed activity was 0.8 mCi, the data were 112.1 Gy and 93.4%, respectively. For irradiated stents in Group I, D 90 and V 100 could not achieve the requirements mentioned above. When the PD was 105 Gy and seed activity was 0.8 mCi, D 90 and V 100 were the largest, and the maximum was 44.9 Gy (43% PD) and 30.1%, respectively.
Image-guided interstitial brachytherapy using 125 I seeds can fully accommodate the contours of the tumor volume, as well as achieve highly accurate conformity and rapid fall-off of dose. A CN >0.6 has been recommended for "conformal radiotherapy."
[21] Table 2 shows that, when the PD (in Gy) was 105, 125, and 145 and the corresponding seed activity (in mCi) was 0.4 and 0.5, 0.5 and 0.6, and 0.6 and 0.7, respectively, the CN of Group III was >0.6. When the PD was 105 and 125 Gy and the corresponding seed activity was 0.7 and 0.8 mCi, respectively, the CN of Group II was 0.61 and 0.60, respectively. The CN of Group I was <0.6. When the PD was 105 Gy and seed activity was 0.8 mCi, the maximum CN was 0.22. Due to the inverse-square law and the law of exponential decay, it is difficult for 125 I seed brachytherapy to ensure the uniformity of dose distribution in the target volume. Therefore, the CN and EI should be more important for the evaluation of brachytherapy plan. In our study, as the activity of 125 I seeds and the number of 125 I seed strands increased, the CN and EI also increased. Hence, increases in the activity of 125 I seeds and number of 125 I seed strands do not always result in a better brachytherapy plan.
A stent combined with a single 125 I seed strand in Group I led to difficulties in meeting the requirements for dosimetry. When the PD was 105 Gy and activity of 125 I seeds was 0.7 mCi, the dose distribution of Group II satisfied the dosimetry requirements of our study. For a portal-vein stent combined with three 125 I seed strands, when the PD (in Gy) was 105, 125, and 145 and the corresponding activity of 125 I seeds (in mCi) was 0.5, 0.5 and 0.6, and 0.6 and 0.7, respectively, the dosimetry could be met. For stents in Group III, when the PD was 125 Gy and activity of 125 I seeds increased from 0.5 mCi to 0.6 mCi, D 90 increased by 20%, V 100 increased by 12%, the CN decreased by 4%, the EI increased by 107%, and the HI decreased by 28%. Therefore, a seed activity of 0.5 mCi could be a rational choice. Similarly, when the PD was 145 Gy and activity of 125 I seeds increased from 0.6 mCi to 0.7 mCi, D 90 increased by 18%, V 100 increased by 9%, the CN decreased by 7%, the EI increased by 91%, and the HI decreased by 25%. Hence, a seed activity of 0.6 mCi could be the best choice.
The present study was in strict accordance with the assessment steps of brachytherapy dosimetry recommended by the American Brachytherapy Society. We explored the dosimetric characteristics of portal-vein stenting combined with different numbers of 125 I seed strands. In the real world, the tumor target would change in the morphology, shape, and size after the stent expansion in the occluded portal vein. Thus, the dosimetry distribution may be different from the water cylinder, so our basic research could only provide a theoretical basis for rational, safe, and effective clinical application. Nevertheless, the clinical experience of brachytherapy using 125 I seeds for luminal tumors is very limited. The PD, activity of 125 I seeds, and criteria for evaluation of dosimetry parameters are mainly those chosen for prostate cancer, which may have led to some bias in our results. In addition, this work is a treatment planning study, the relative position of adjacent critical structures (mainly liver, kidneys, stomach, and small intestine) to target volume, the relative position between the critical structures, and the volume of the critical structures are difficult to determine in our study. Thus, we did not take into account the doses to adjacent critical structures. Furthermore, portal-vein stents combined with two or three 125 I seed strands were simulated by a particular TPS, and its clinical feasibility and safety requires verification.
In conclusion, it was difficult for a portal-vein stent combined with a single 125 I seed strand to meet the requirements for clinical dosimetry. For a stent combined with two 125 I seed strands, when the PD was 105 Gy and the activity of 125 I seeds was 0.7 mCi, the dose distribution could satisfy the dosimetry requirements of our study. For a stent combined with three 125 I seed strands, if the PD was 105, 125, or 145 Gy, the recommended seed activities were 0.5, 0.5, and 0.6 mCi, respectively.
